NO2944633T3 - - Google Patents

Info

Publication number
NO2944633T3
NO2944633T3 NO13854714A NO13854714A NO2944633T3 NO 2944633 T3 NO2944633 T3 NO 2944633T3 NO 13854714 A NO13854714 A NO 13854714A NO 13854714 A NO13854714 A NO 13854714A NO 2944633 T3 NO2944633 T3 NO 2944633T3
Authority
NO
Norway
Application number
NO13854714A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2944633T3 publication Critical patent/NO2944633T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
NO13854714A 2012-11-14 2013-11-13 NO2944633T3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012250661 2012-11-14
PCT/JP2013/080706 WO2014077285A1 (ja) 2012-11-14 2013-11-13 ピリジン誘導体

Publications (1)

Publication Number Publication Date
NO2944633T3 true NO2944633T3 (no) 2018-06-30

Family

ID=50731196

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13854714A NO2944633T3 (no) 2012-11-14 2013-11-13

Country Status (36)

Country Link
US (2) US9637469B2 (no)
EP (2) EP3339302A1 (no)
JP (2) JP5774238B2 (no)
KR (1) KR20150082194A (no)
CN (2) CN107721931A (no)
AR (1) AR093468A1 (no)
AU (2) AU2013345894B2 (no)
BR (1) BR112015010977A2 (no)
CA (1) CA2891408A1 (no)
CL (1) CL2015001279A1 (no)
CY (1) CY1120127T1 (no)
DK (1) DK2944633T3 (no)
ES (1) ES2662444T3 (no)
HK (1) HK1211940A1 (no)
HR (1) HRP20180451T1 (no)
HU (1) HUE037736T2 (no)
IL (2) IL238539A (no)
LT (1) LT2944633T (no)
MA (1) MA38078B1 (no)
ME (1) ME03016B (no)
MX (1) MX2015003672A (no)
NO (1) NO2944633T3 (no)
NZ (1) NZ708031A (no)
PE (1) PE20150974A1 (no)
PH (1) PH12015501037A1 (no)
PL (1) PL2944633T3 (no)
PT (1) PT2944633T (no)
RS (1) RS57090B1 (no)
RU (1) RU2640588C2 (no)
SA (1) SA515360431B1 (no)
SG (2) SG10201705852PA (no)
SI (1) SI2944633T1 (no)
TW (1) TWI666205B (no)
UA (1) UA117359C2 (no)
WO (1) WO2014077285A1 (no)
ZA (1) ZA201503322B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948797A1 (en) * 2014-05-13 2015-11-19 Teijin Pharma Limited Pyrazine derivatives
SG11201609483YA (en) * 2014-05-13 2016-12-29 Teijin Pharma Ltd Novel crystalline polymorphs of pyridine derivative and method for producing the same
MX2018011214A (es) 2016-03-15 2019-03-28 Bayer Cropscience Ag Sulfonamidas sustituidas para controlar plagas animales.
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
EP3466946B1 (en) 2016-05-23 2023-08-30 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Thiophene, manufacturing method thereof, and pharmaceutical application of same
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
TW201837036A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物(一)
EP3568395A1 (de) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
CN108658879A (zh) * 2017-03-29 2018-10-16 天津药物研究院有限公司 一种urat1抑制剂及其制备方法和用途
CN109251184B (zh) * 2017-07-13 2021-06-15 浙江海正药业股份有限公司 一种2-三氟甲基苯磺酰胺类衍生物的医药用途
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
JP2023501978A (ja) 2019-11-07 2023-01-20 バイエル・アクチエンゲゼルシヤフト 動物害虫駆除用の置換スルホニルアミド
CN116033828A (zh) 2020-07-02 2023-04-28 拜耳公司 作为害虫防治剂的杂环衍生物
CN114315729B (zh) * 2021-12-09 2024-01-26 大连理工大学 1-苄基-2,4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1599032A (en) 1977-03-04 1981-09-30 May & Baker Ltd Imidazole derivatives having herbicidal activity
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
US4770689A (en) 1986-03-10 1988-09-13 Janssen Pharmaceutica N.V. Herbicidal imidazole-5-carboxylic acid derivatives
PL149675B1 (pl) * 1986-03-10 1990-03-31 Sposób wytwarzania nowych pochodnych kwasu 1-metyl0-1h-imidaz0l0karb0ksyl0weg0-5
US4851424A (en) 1986-06-06 1989-07-25 Ciba-Geigy Corporation 1-Phenyl-lower alkyl-imidazole 4- or 5-carboxamide compounds which are useful in the treatment of epilepsy
DD260928A5 (de) * 1986-06-06 1988-10-12 Ciba-Geigy Ag,Ch Verfahren zur herstellung neuer aralkylimidizolderivate
JPH08119936A (ja) 1994-10-18 1996-05-14 Fujisawa Pharmaceut Co Ltd 複素環式誘導体
IT1295405B1 (it) * 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
CN1466572A (zh) * 2000-07-28 2004-01-07 ס����ҩ��ʽ���� 吡咯衍生物
EP1792614A1 (en) 2001-02-22 2007-06-06 Teijin Pharma Limited Benzo[b]thiophene derivatives
AU2003902828A0 (en) * 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
EP2842948A1 (en) * 2007-11-27 2015-03-04 Ardea Biosciences, Inc. Novel compounds and compositions and methods of use
US8450500B2 (en) * 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
MX2011002449A (es) 2008-09-04 2011-05-25 Ardea Biosciences Inc Compuestos, composiciones y métodos para utilizar los mismos para modular niveles de ácido úrico.
JP2010202575A (ja) * 2009-03-03 2010-09-16 Takeda Chem Ind Ltd 複素環化合物
CN102548964B (zh) * 2009-07-10 2014-09-24 通用医疗公司 不抑制肾上腺皮质类固醇合成的依托咪酯类似物
CN102035579B (zh) * 2009-09-28 2014-09-03 夏普株式会社 信息反馈方法和用户设备
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
JP5485811B2 (ja) * 2010-06-23 2014-05-07 株式会社ジャパンディスプレイ 双方向シフトレジスタ、及びこれを用いた画像表示装置
PE20131304A1 (es) * 2010-08-11 2013-11-14 Millennium Pharm Inc Heteroarilos y sus usos

Also Published As

Publication number Publication date
JPWO2014077285A1 (ja) 2017-01-05
CY1120127T1 (el) 2018-12-12
RS57090B1 (sr) 2018-06-29
PL2944633T3 (pl) 2018-08-31
ZA201503322B (en) 2016-01-27
MX2015003672A (es) 2015-06-15
TW201422603A (zh) 2014-06-16
RU2015122698A (ru) 2017-01-10
BR112015010977A2 (pt) 2017-07-11
PT2944633T (pt) 2018-05-09
RU2640588C2 (ru) 2018-01-10
ES2662444T3 (es) 2018-04-06
CL2015001279A1 (es) 2015-06-26
AU2013345894A9 (en) 2015-11-12
MA38078A1 (fr) 2016-09-30
AR093468A1 (es) 2015-06-10
UA117359C2 (uk) 2018-07-25
NZ708031A (en) 2018-04-27
ME03016B (me) 2018-10-20
US9637469B2 (en) 2017-05-02
EP2944633B1 (en) 2018-01-31
TWI666205B (zh) 2019-07-21
CN104797570B (zh) 2017-11-07
SG10201705852PA (en) 2017-08-30
IL243193A0 (en) 2016-02-29
HRP20180451T1 (hr) 2018-06-01
CN104797570A (zh) 2015-07-22
JP5774238B2 (ja) 2015-09-09
LT2944633T (lt) 2018-03-12
SG11201503770VA (en) 2015-06-29
EP2944633A1 (en) 2015-11-18
KR20150082194A (ko) 2015-07-15
CN107721931A (zh) 2018-02-23
IL238539A0 (en) 2015-06-30
DK2944633T3 (en) 2018-03-12
AU2013345894B2 (en) 2017-05-25
HUE037736T2 (hu) 2018-09-28
JP6293068B2 (ja) 2018-03-14
PH12015501037A1 (en) 2015-07-27
US20170190694A1 (en) 2017-07-06
AU2013345894A1 (en) 2015-05-21
HK1211940A1 (en) 2016-06-03
JP2015091865A (ja) 2015-05-14
AU2017204665A1 (en) 2017-07-27
US20150284358A1 (en) 2015-10-08
PE20150974A1 (es) 2015-07-04
EP2944633A4 (en) 2016-01-06
CA2891408A1 (en) 2014-05-22
WO2014077285A1 (ja) 2014-05-22
IL238539A (en) 2017-11-30
EP3339302A1 (en) 2018-06-27
SI2944633T1 (en) 2018-06-29
SA515360431B1 (ar) 2017-11-15
MA38078B1 (fr) 2017-04-28

Similar Documents

Publication Publication Date Title
BR112014020022A2 (no)
BR112014017635A2 (no)
BR112014017614A2 (no)
BR112014017592A2 (no)
BR112014017625A2 (no)
BR112014017659A2 (no)
BR112014017646A2 (no)
BR112014017638A2 (no)
BR112014017607A2 (no)
BR112014018493A2 (no)
NO2944633T3 (no)
BR112014017634A2 (no)
BR112014017609A2 (no)
BR112014017673A2 (no)
BR112014017644A2 (no)
BR112014017647A2 (no)
BR112014017588A2 (no)
BR112014017618A2 (no)
BR112014017630A2 (no)
BR112014019162A2 (no)
BR112014017652A2 (no)
BR112014017621A2 (no)
BR112014017622A2 (no)
BR112014017627A2 (no)
BR112014017623A2 (no)